Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Vericel Corporation Trends and Insights

Biotech Giants' SG&A Expenses: A Decade of Growth and Strategy

__timestampUltragenyx Pharmaceutical Inc.Vericel Corporation
Wednesday, January 1, 20141081100013774000
Thursday, January 1, 20153300100022479000
Friday, January 1, 20166493600027388000
Sunday, January 1, 20179990900035610000
Monday, January 1, 201812772400049007000
Tuesday, January 1, 201916152400061139000
Wednesday, January 1, 202018293300068836000
Friday, January 1, 202121998200097592000
Saturday, January 1, 2022278139000106903000
Sunday, January 1, 2023309799000120998000
Loading chart...

Cracking the code

SG&A Expenses: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial. This article delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Ultragenyx Pharmaceutical Inc. and Vericel Corporation, from 2014 to 2023.

Ultragenyx Pharmaceutical Inc.

Ultragenyx has seen a staggering increase in SG&A expenses, growing nearly 2,800% over the decade. This reflects their aggressive expansion and investment in administrative capabilities, crucial for supporting their innovative therapies.

Vericel Corporation

Vericel, while smaller, has also experienced a significant rise in SG&A expenses, increasing by approximately 780%. This growth underscores their commitment to scaling operations and enhancing market presence.

Key Insights

Both companies show a consistent upward trend, with Ultragenyx's expenses peaking at over 2.5 times that of Vericel by 2023. This financial trajectory highlights the competitive nature of the biotech industry, where strategic spending is key to sustaining growth and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025